+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acinetobacter Infections - Pipeline Review, H1 2020

  • ID: 5024739
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 192 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • AstraZeneca Plc
  • Destiny Pharma Plc
  • Inhibrx Inc
  • Neoculi Pty Ltd
  • Pylum Biosciences Inc
  • MORE
Acinetobacter Infections - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2020, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 40 and 20 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 8 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • AstraZeneca Plc
  • Destiny Pharma Plc
  • Inhibrx Inc
  • Neoculi Pty Ltd
  • Pylum Biosciences Inc
  • MORE
  • Introduction
  • Acinetobacter Infections - Overview
  • Acinetobacter Infections - Therapeutics Development
  • Acinetobacter Infections - Therapeutics Assessment
  • Acinetobacter Infections - Companies Involved in Therapeutics Development
  • Acinetobacter Infections - Drug Profiles
  • Acinetobacter Infections - Dormant Projects
  • Acinetobacter Infections - Discontinued Products
  • Acinetobacter Infections - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Acinetobacter Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Acinetobacter Infections - Pipeline by ABAC Therapeutics SA, H1 2020
  • Acinetobacter Infections - Pipeline by Acies Bio doo, H1 2020
  • Acinetobacter Infections - Pipeline by AGILeBiotics BV, H1 2020
  • Acinetobacter Infections - Pipeline by AiCuris GmbH & Co KG, H1 2020
  • Acinetobacter Infections - Pipeline by Antabio SAS, H1 2020
  • Acinetobacter Infections - Pipeline by Appili Therapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
  • Acinetobacter Infections - Pipeline by AstraZeneca Plc, H1 2020
  • Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Aurora Oncology Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Bioharmony Therapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Biological Anti-Infective Medicines LLC, H1 2020
  • Acinetobacter Infections - Pipeline by Biomendics LLC, H1 2020
  • Acinetobacter Infections - Pipeline by Bugworks Research India Pvt Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Celdara Medical LLC, H1 2020
  • Acinetobacter Infections - Pipeline by Centauri Therapeutics Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by ContraFect Corp, H1 2020
  • Acinetobacter Infections - Pipeline by Debiopharm International SA, H1 2020
  • Acinetobacter Infections - Pipeline by Destiny Pharma Plc, H1 2020
  • Acinetobacter Infections - Pipeline by Eligochem Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by EnBiotix Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Fedora Pharmaceuticals Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H1 2020
  • Acinetobacter Infections - Pipeline by Inhibrx Inc, H1 2020
  • Acinetobacter Infections - Pipeline by KBP BioSciences Co Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Linnaeus Bioscience Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Mutabilis SA, H1 2020
  • Acinetobacter Infections - Pipeline by Neoculi Pty Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Novabiotics Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Octagon Therapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Omnix Medical Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Oxford Drug Design Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Peptilogics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Pylum Biosciences Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Qpex Biopharma Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Redx Pharma Plc, H1 2020
  • Acinetobacter Infections - Pipeline by RMH Sciences LLC, H1 2020
  • Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2020
  • Acinetobacter Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Spero Therapeutics Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Summit Therapeutics Plc, H1 2020
  • Acinetobacter Infections - Pipeline by The Broad Institute Inc, H1 2020
  • Acinetobacter Infections - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020
  • Acinetobacter Infections - Pipeline by Venus Medicine Research Center, H1 2020
  • Acinetobacter Infections - Pipeline by Vitas Pharma Research Pvt Ltd, H1 2020
  • Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H1 2020
  • Acinetobacter Infections - Dormant Projects, H1 2020
  • Acinetobacter Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Acinetobacter Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Acinetobacter Infections - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Acinetobacter Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ABAC Therapeutics SA
  • Acies Bio doo
  • AGILeBiotics BV
  • AiCuris GmbH & Co KG
  • Antabio SAS
  • Appili Therapeutics Inc
  • Aridis Pharmaceuticals Inc
  • Armata Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atterx Biotherapeutics Inc
  • Aurora Oncology Inc
  • Bioharmony Therapeutics Inc
  • Biological Anti-Infective Medicines LLC
  • Biomendics LLC
  • Bugworks Research India Pvt Ltd
  • Celdara Medical LLC
  • Centauri Therapeutics Ltd
  • ContraFect Corp
  • Debiopharm International SA
  • Destiny Pharma Plc
  • Eligochem Ltd
  • EnBiotix Inc
  • Entasis Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fedora Pharmaceuticals Inc
  • Hsiri Therapeutics LLC
  • Inhibrx Inc
  • KBP BioSciences Co Ltd
  • Linnaeus Bioscience Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Mutabilis SA
  • Neoculi Pty Ltd
  • Novabiotics Ltd
  • Octagon Therapeutics Inc
  • Omnix Medical Ltd
  • Oxford Drug Design Ltd
  • Peptilogics Inc
  • Pylum Biosciences Inc
  • Qpex Biopharma Inc
  • Redx Pharma Plc
  • RMH Sciences LLC
  • Sealife PHARMA GMBH
  • Shanghai Space Peptides Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Spero Therapeutics Inc
  • Summit Therapeutics Plc
  • The Broad Institute Inc
  • VenatoRx Pharmaceuticals Inc
  • Venus Medicine Research Center
  • Vitas Pharma Research Pvt Ltd
  • Xellia Pharmaceuticals ApS
Note: Product cover images may vary from those shown
Adroll
adroll